Molecular characterization of triple negative breast cancer formaldehyde-fixed paraffin-embedded samples by data-independent acquisition proteomics.
molecular characterization
personalized medicine
proteomics
triple negative breast cancer
Journal
Proteomics
ISSN: 1615-9861
Titre abrégé: Proteomics
Pays: Germany
ID NLM: 101092707
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
14
09
2021
received:
19
04
2021
accepted:
29
09
2021
pubmed:
9
10
2021
medline:
23
3
2022
entrez:
8
10
2021
Statut:
ppublish
Résumé
Triple negative breast cancer accounts for 15%-20% of all breast carcinomas and is clinically characterized by an aggressive phenotype and poor prognosis. Triple negative tumors do not benefit from targeted therapies, so further characterization is needed to define subgroups with potential therapeutic value. In this work, the proteomes of 125 formalin-fixed paraffin-embedded samples from patients diagnosed with non-metastatic triple negative breast cancer were analyzed using data-independent acquisition + in a LTQ-Orbitrap Fusion Lumos mass spectrometer coupled to an EASY-nLC 1000. 1206 proteins were identified in at least 66% of the samples. Hierarchical clustering, probabilistic graphical models and Significance Analysis of Microarrays were combined to characterize proteomics-based molecular groups. Two molecular groups were defined with differences in biological processes such as glycolysis, translation and immune response. These two molecular groups showed also several differentially expressed proteins. This clinically homogenous dataset may serve to design new therapeutic strategies in the future.
Identifiants
pubmed: 34624180
doi: 10.1002/pmic.202100110
doi:
Substances chimiques
Proteome
0
Formaldehyde
1HG84L3525
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2100110Informations de copyright
© 2021 Wiley-VCH GmbH.
Références
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007). Triple-negative breast cancer: Clinical features and patterns of recurrence. Clinical Cancer Research, 13(15 Pt 1), 4429-4434. https://doi.org/10.1158/1078-0432.CCR-06-3045
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F, Gonzalez-Angulo, A. M., Hennessy, B., Green, M., Cristofanilli, M., Hortobagyi, G. N., & Pusztai, L. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology, 26(8), 1275-1281. https://doi.org/10.1200/jco.2007.14.4147
Reddy, S. M., Barcenas, C. H., Sinha, A. K., Hsu, L., Moulder, S. L., Tripathy, D., Hortobagyi, G. N., & Valero, V. (2018). Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. British Journal of Cancer, 118(1), 17-23. https://doi.org/10.1038/bjc.2017.379
Tischkowitz, M., Brunet, J.-S., Bégin, L. R., Huntsman, D. G., Cheang, M. C., Akslen, L. A., Nielsen, T. O., Foulkes, W. D. (2007). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer [Electronic Resource], 7, 134. https://doi.org/10.1186/1471-2407-7-134
Harrell, J. C, Prat, A., Parker, J. S., Fan, C., He, X., Carey, L., Anders, C., Ewend, M., & Perou, C. M. (2012). Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Research and Treatment, 132(2), 523-535. https://doi.org/10.1007/s10549-011-1619-7
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010). Metastatic behavior of breast cancer subtypes. Journal of Clinical Oncology, 28(20), 3271-3277. https://doi.org/10.1200/JCO.2009.25.9820
Lin, N. U., Vanderplas, A., Hughes, M. E., Theriault, R. L., Edge, S. B., Wong, Y.-N., Blayney, D. W., Niland, J. C., Winer, E. P., & Weeks, J. C. (2012). Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer, 118(22), 5463-5472. https://doi.org/10.1002/cncr.27581
Rodríguez-Pinilla, S. M., Sarrió, D., Honrado, E., Hardisson, D., Calero, F., Benitez, J., & Palacios, J. (2006). Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clinical Cancer Research, 12(5), 1533-1539. https://doi.org/10.1158/1078-0432.CCR-05-2281
Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A. M., Yu, J., Klijn, J. G. M., Foekens, J. A., & Martens, J. W. M. (2008). Subtypes of breast cancer show preferential site of relapse. Cancer Research, 68(9), 3108-3114. https://doi.org/10.1158/0008-5472.CAN-07-5644
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K, Hilsenbeck, S. G., Chang, J. C., Mills, G. B., Lau, C. C., & Brown, P. H. (2015). Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Research, 21(7), 1688-1698. https://doi.org/10.1158/1078-0432.CCR-14-0432
Jézéquel, P., Loussouarn, D., Guérin-Charbonnel, C., Campion, L., Vanier, A., Gouraud, W., Lasla, H., Guette, C., Valo, I., Verrièle, V., & Campone, M. (2015). Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Research, 17, 43. https://doi.org/10.1186/s13058-015-0550-y
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B, Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation, 121(7), 2750-2767. https://doi.org/10.1172/JCI45014
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016). Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. Plos One, 11(6), e0157368. https://doi.org/10.1371/journal.pone.0157368
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., Symmans, W. F, & Ueno, N. T. (2013). Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clinical Cancer Research, 19(19), 5533-5540. https://doi.org/10.1158/1078-0432.CCR-13-0799
Lawrence, R. T., Perez, E. M., Hernández, D., Miller, C. P., Haas, K. M., Irie, H. Y., Lee, S.-I., Blau, C. A, & Villén, J. (2015). The proteomic landscape of triple-negative breast cancer. Cell Reports, 11(6), 630. https://doi.org/10.1016/j.celrep.2015.04.059
Bruderer, R., Muntel, J., Müller, S., Bernhardt, O. M., Gandhi, T., Cominetti, O., Macron, C., Carayol, J., Rinner, O., Astrup, A., Saris, W. H. M., Hager, J., Valsesia, A., Dayon, L., & Reiter, L. (2019). Analysis of 1508 plasma samples by capillary-flow data-independent acquisition profiles proteomics of weight loss and maintenance. Molecular and Cellular Proteomics, 18(6), 1242-1254. https://doi.org/10.1074/mcp.RA118.001288
Gillet, L. C., Navarro, P., Tate, S., Röst, H., Selevsek, N., Reiter, L., Bonner, R., & Aebersold, R. (2012). Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: A new concept for consistent and accurate proteome analysis. Molecular and Cellular Proteomics, 11(6), O111.016717. https://doi.org/10.1074/mcp.O111.016717
Borràs, E., & Sabidó, E. (2018). DIA+: A data-independent acquisition method combining multiple precursor charges to improve peptide signal. Analytical Chemistry, 90(21), 12339-12341. https://doi.org/10.1021/acs.analchem.8b03418
Egertson, J. D., Kuehn, A., Merrihew, G. E., Bateman, N. W., Maclean, B. X., Ting, Y. S., Canterbury, J. D., Marsh, D. M., Kellmann, M., Zabrouskov, V., Wu, C. C., & Maccoss, M. J. (2013). Multiplexed MS/MS for improved data-independent acquisition. Nature Methods, 10(8), 744-746. https://doi.org/10.1038/nmeth.2528
Kiyonami, R., Senko, M., Zabrouskov, V., Hühmer, A., Egertson, J., Ting, S., & MacCoss, M. (2014). Large scale targeted protein quantification using WiSIM-DIA workflow on a orbitrap fusion tribrid mass spectrometer. In. Thermo Scientific Application Note 600.
Bouchal, P., Schubert, O. T., Faktor, J., Capkova, L., Imrichova, H., Zoufalova, K., Paralova, V., Hrstka, R., Liu, Y., Ebhardt, H. A., Budinska, E., Nenutil, R., & Aebersold, R. (2019). Breast cancer classification based on proteotypes obtained by SWATH mass spectrometry. Cell Reports, 28(3), 832-843.e7.e837. https://doi.org/10.1016/j.celrep.2019.06.046
Collins, B. C., Hunter, C. L., Liu, Y., Schilling, B., Rosenberger, G., Bader, S. L., Chan, D. W., Gibson, B. W., Gingras, A.-C., Held, J. M., Hirayama-Kurogi, M., Hou, G., Krisp, C., Larsen, B., Lin, L., Liu, S., Molloy, M. P., Moritz, R. L., Ohtsuki, S., Schlapbach, R., Selevsek, N., Thomas, S. N., Tzeng, S.-C., Zhang, H., & Aebersold, R. (2017). Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry. Nature Communications, 8(1), 291. https://doi.org/10.1038/s41467-017-00249-5
Gámez-Pozo, A., Trilla-Fuertes, L., Berges-Soria, J., Selevsek, N., López-Vacas, R., Díaz-Almirón, M., Nanni, P., Arevalillo, J. M., Navarro, H., Grossmann, J., Gayá Moreno, F., Gómez Rioja, R., Prado-Vázquez, G., Zapater-Moros, A., Main, P., Feliú, J., Martínez Del Prado, P., Zamora, P., Ciruelos, E., Espinosa, E., & Fresno Vara, J. Á. (2017). Functional proteomics outlines the complexity of breast cancer molecular subtypes. Scientific Reports, 7(1), 10100. https://doi.org/10.1038/s41598-017-10493-w
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer, 109(9), 1721-1728. https://doi.org/10.1002/cncr.22618
Campone, M., Valo, I., Jézéquel, P., Moreau, M., Boissard, A., Campion, L., Loussouarn, D., Verriele, V., Coqueret, O., & Guette, C. (2015). Prediction of recurrence and survival for triple-negative breast cancer (TNBC) by a protein signature in tissue samples. Molecular and Cellular Proteomics, 14(11), 2936-2946. https://doi.org/10.1074/mcp.M115.048967
Dawood, S., Broglio, K., Esteva, F. J., Yang, W., Kau, S.-W., Islam, R., Albarracin, C., Yu, T. K., Green, M., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009). Survival among women with triple receptor-negative breast cancer and brain metastases. Annals of Oncology, 20(4), 621-627. https://doi.org/10.1093/annonc/mdn682
Gámez-Pozo, A., Ferrer, N. I., Ciruelos, E., López-Vacas, R., Martínez, F. G., Espinosa, E., & Vara, J. Á. F. (2013). Shotgun proteomics of archival triple-negative breast cancer samples. Proteomics Clin Appl, 7(3-4), 283-291. https://doi.org/10.1002/prca.201200048
Chiva, C., Olivella, R., Borràs, E., Espadas, G., Pastor, O., Solé, A., & Sabidó, E. (2018). QCloud: A cloud-based quality control system for mass spectrometry-based proteomics laboratories. Plos One, 13(1), e0189209. https://doi.org/10.1371/journal.pone.0189209
Tsou, C.-C., Avtonomov, D., Larsen, B., Tucholska, M., Choi, H., Gingras, A.-C., & Nesvizhskii, A. I. (2015). DIA-Umpire: comprehensive computational framework for data-independent acquisition proteomics. Nature Methods, 12(3), 258-264, 257 p following 264. https://doi.org/10.1038/nmeth.3255
Choi, M., Chang, C.-Y., Clough, T., Broudy, D., Killeen, T., Maclean, B., & Vitek, O. (2014). MSstats: An R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. Bioinformatics, 30(17), 2524-2526. https://doi.org/10.1093/bioinformatics/btu305
Hu, A., Noble, W. S., & Wolf-Yadlin, A. (2016). Technical advances in proteomics: New developments in data-independent acquisition. F1000Res, 5,419. https://doi.org/10.12688/f1000research.7042.1
Ludwig, C., Gillet, L., Rosenberger, G., Amon, S., Collins, B. C., & Aebersold, R. (2018). Data-independent acquisition-based SWATH-MS for quantitative proteomics: A tutorial. Molecular Systems Biology, 14(8), e8126. https://doi.org/10.15252/msb.20178126
Saeed, A. I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M., Sturn, A., Snuffin, M., Rezantsev, A., Popov, D., Ryltsov, A., Kostukovich, E., Borisovsky, I., Liu, Z., Vinsavich, A., Trush, V., & Quackenbush, J. (2003). TM4: A free, open-source system for microarray data management and analysis. Biotechniques, 34(2), 374-378.
Tusher, V. G., Tibshirani, R., & Chu, G. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America, 98(9), 5116-5121. https://doi.org/10.1073/pnas.091062498
Trilla-Fuertes, L., Gámez-Pozo, A., Arevalillo, J. M., Díaz-Almirón, M., Prado-Vázquez, G., Zapater-Moros, A., Navarro, H., Aras-López, R., Dapía, I., López-Vacas, R., Nanni, P., Llorente-Armijo, S., Arias, P., Borobia, A. M., Maín, P., Feliú, J., Espinosa, E., & Fresno Vara, J. Á. (2018). Molecular characteization of breast cancer cell response to metabolic drugs. Oncotarget, 9(11), 9645-9660. https://doi.org/10.18632/oncotarget.24047
Akkiprik, M., Feng, Y., Wang, H., Chen, K., Hu, L., Sahin, A., Krishnamurthy, S., Ozer, A., Hao, X., & Zhang, W. (2008). Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. Breast Cancer Research, 10(4), 212. https://doi.org/10.1186/bcr2116
Abreu, G. C. G., Edwards, D., & Labouriau, R. (2010). High-dimensional graphical model search with the gRapHD R package. In (Vol. 37, pp. 1-18). Journal of Statistical Software.
Lauritzen, S. (1996). Graphical models. Oxford, UK. Oxford University Press.
Huang, D. W, Sherman, B. T., & Lempicki, R. A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols, 4(1), 44-57. https://doi.org/10.1038/nprot.2008.211
De Velasco, G., Trilla-Fuertes, L., Gamez-Pozo, A., Urbanowicz, M., Ruiz-Ares, G., Sepúlveda, J. M., Prado-Vazquez, G., Arevalillo, J. M., Zapater-Moros, A., Navarro, H., Lopez-Vacas, R., Manneh, R., Otero, I., Villacampa, F., Paramio, J. M., Vara, J. A. F., & Castellano, D. (2017). Urothelial cancer proteomics provides both prognostic and functional information. Scientific Reports, 7(1), 15819. https://doi.org/10.1038/s41598-017-15920-6
Gámez-Pozo, A., Berges-Soria, J., Arevalillo, J. M., Nanni, P., López-Vacas, R., Navarro, H., Grossmann, J., Castaneda, C. A., Main, P., Díaz-Almirón, M., Espinosa, E., Ciruelos, E., & Fresno Vara, J. Á. (2015). Combined label-free quantitative proteomics and microRNA expression analysis of breast cancer unravel molecular differences with clinical implications. In (Vol. 75, pp. 2243-2253): Cancer Research.
Gámez-Pozo, A., Trilla-Fuertes, L., Prado-Vázquez, G., Chiva, C., López-Vacas, R., Nanni, P., Berges-Soria, J., Grossmann, J., Díaz-Almirón, M., Ciruelos, E., Sabidó, E., Espinosa, E., & Fresno Vara, J. Á. (2017). Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics. Plos One, 12(6), e0178296. https://doi.org/10.1371/journal.pone.0178296
Schmid, P., Chui, S. Y., & Emens, L. A. (2019). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. Reply. New England Journal of Medicine, 380(10), 985-988. https://doi.org/10.1056/NEJMc1900150
Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., Pérez, E., Uszkoreit, J., Pfeuffer, J., Sachsenberg, T., Yılmaz, Ş., Tiwary, S., Cox, J., Audain, E., Walzer, M., Jarnuczak, A. F., Ternent, T., Brazma, A., & Vizcaíno, J. A. (2019). The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucleic Acids Research, 47(D1), D442-D450. https://doi.org/10.1093/nar/gky1106